Trials / Withdrawn
WithdrawnNCT01240928
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.
Detailed description
The phase II portion of this trial will be listed under a separate NCT number.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSK-2206 | Level 1: MK-2206 135mg weekly |
| DRUG | Exemestane | Level 1: Exemestane - 25mg daily |
| DRUG | Goserelin | Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only |
Timeline
- First posted
- 2010-11-15
- Last updated
- 2013-08-20
Source: ClinicalTrials.gov record NCT01240928. Inclusion in this directory is not an endorsement.